David Spigel, MD
Enriched profilePresident and Chief Medical Officer, Sarah Cannon Research Institute (effective January 2026; formerly Chief Scientific Officer, succeeding retiring Howard "Skip" Burris III, MD) · Sarah Cannon Research Institute
David Spigel is President and Chief Medical Officer, Sarah Cannon Research Institute (effective January 2026; formerly Chief Scientific Officer, succeeding retiring Howard "Skip" Burris III, MD) at Sarah Cannon Research Institute. OpenAlex indexes 909 publications with 79,383 citations (h-index 99); ClinicalTrials.gov lists 39 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists David Spigel as a Highly Cited Researcher (Clinical Medicine, 2019-2025).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
David R. Spigel, M.D., is President and Chief Medical Officer, Sarah Cannon Research Institute (effective January 2026. The public record shows 909 publications with 79,383 citations (h-index 99), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 39 registered clinical trials, industry payments reported by 50 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 39 registered trials on ClinicalTrials.gov
- Open Payments reporting from 50 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 371.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Editor for Targeted Therapies
Oncology & Biotech News, Contemporary Oncology, and World Journal of Clinical Oncology; peer reviewer for numerous other journals (per secondary source …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma.net ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 39 registered studies on ClinicalTrials.gov. The most recent:
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Sponsor: SCRI Development Innovations, LLC
- Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Sponsor: SCRI Development Innovations, LLC
Industry payments
Updated 14 Oct 2026
50 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202514 payments$12,752openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20253 payments
- ABBVIE INC.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
76.3%Corticosteroid76.3%Dexamethasone sodium phosphate100%Part B, office-administered≥24 patientsCancer & immunology
6.5%Kinase inhibitor5.2%Tagrisso53%Tepmetko26%Tabrecta22%Part D<11 patientsCytochrome P450 17A1 Inhibitor1.2%Abiraterone Acetate100%Part D<11 patientsNervous system
6.3%Opioid Agonist4.3%Oxycodone Hcl41%Fentanyl33%Morphine Sulfate Er26%Part D<11 patientsPhenothiazine2%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Clinical cancer research
Clinical Trial2026 - Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.
Advances in therapy
Clinical Trial2026 - Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer12,657 citations2012
- 02
- 03
- 04Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC2,802 citations2018
- 05Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC1,692 citations2020
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/D-R-Spigel-2099152522
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/davidrspigel
- Doximity
doximity.com/pub/david-spigel-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/sarahcannonresearch/videos/june-is-cancer-immunotherapy-month-and-dr-david-spigel-of-sarah-cannon-research-/2420270155023501
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/reel/DL-3ZNFsEuH
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/company/sarah-cannon-research-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
researchevangelist.com/podcast/episode-43-dr-david-spigel-dave-bjork-research-evangelist-2021
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchevangelist.com ↗ - Other
scri.com/news/meet-david-spigel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scri.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X/Twitter handle @DavidRSpigel, listed as "David R. Spigel, MD, FASCO"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
- Internal Medicine residency and chief residency
Indiana University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - Fellowship in Hematology/Oncology
Dana-Farber Cancer Institute, Boston
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
- Director
Lung Cancer Research Program, Sarah Cannon Research Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma.net ↗ - Medical oncologist / Partner
Tennessee Oncology, PLLC, Nashville TN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2019202020212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗
Secondary affiliations
appointments beyond the home institution- Board member
Association of Community Cancer Centers (ACCC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - Member
American Association for Cancer Research (AACR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - Member
International Association for the Study of Lung Cancer (IASLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗ - Member
Lung Cancer Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →centennialmedicine.com ↗
Media & interviews
press, podcasts and appearances- Podcast guest
"The Research Evangelist," Episode 43 (2021), profiled as thoracic medical oncologist and Chief Scientific Officer, Sarah Cannon Research Institute
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchevangelist.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Burris, MD
Sarah Cannon Research Institute
John Hainsworth, MD
Sarah Cannon Research Institute
Jesus Berdeja, MD
Sarah Cannon Research Institute
Denise A. Yardley
Sarah Cannon Research Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center